Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMLX
stocks logo

AMLX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-0.377
-31.43%
--
--
-0.370
-11.9%
--
--
-0.375
-18.48%
Estimates Revision
The market is revising No Change the revenue expectations for Amylyx Pharmaceuticals, Inc. (AMLX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 42.06%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.48%
In Past 3 Month
Stock Price
Go Up
up Image
+42.06%
In Past 3 Month
Wall Street analysts forecast AMLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMLX is 20.22 USD with a low forecast of 16.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast AMLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMLX is 20.22 USD with a low forecast of 16.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.490
sliders
Low
16.00
Averages
20.22
High
25.00
Current: 14.490
sliders
Low
16.00
Averages
20.22
High
25.00
Mizuho
Graig Suvannavejh
Outperform
maintain
$16 -> $18
2025-11-10
Reason
Mizuho
Graig Suvannavejh
Price Target
$16 -> $18
2025-11-10
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Amylyx to $18 from $16 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q3 report.
H.C. Wainwright
Andrew Fein
maintain
$16 -> $20
2025-11-07
Reason
H.C. Wainwright
Andrew Fein
Price Target
$16 -> $20
2025-11-07
maintain
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on Amylyx to $20 from $16 and keeps a Buy rating on the shares. With the pivotal LUCIDITY trial on track for topline data in 2026, the firm remains "enthusiastic about avexitide" and thinks it is positioned to become the first potential therapy for PBH, the analyst tells investors.
Mizuho
Outperform
upgrade
$12 -> $16
2025-10-29
Reason
Mizuho
Price Target
$12 -> $16
2025-10-29
upgrade
Outperform
Reason
Mizuho raised the firm's price target on Amylyx to $16 from $12 and keeps an Outperform rating on the shares.
Citi
Hold -> Buy
upgrade
$12 -> $20
2025-10-17
Reason
Citi
Price Target
$12 -> $20
2025-10-17
upgrade
Hold -> Buy
Reason
Citi raised the firm's price target on Amylyx to $20 from $12 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
Baird
Joel Beatty
Outperform
upgrade
$10 -> $19
2025-10-16
Reason
Baird
Joel Beatty
Price Target
$10 -> $19
2025-10-16
upgrade
Outperform
Reason
Baird analyst Joel Beatty raised the firm's price target on Amylyx to $19 from $10 and keeps an Outperform rating on the shares. The firm updated its model given increased confidence in Avextide's penetration rate in PBH.
Guggenheim
Seamus Fernandez
Buy
upgrade
$17 -> $25
2025-09-15
Reason
Guggenheim
Seamus Fernandez
Price Target
$17 -> $25
2025-09-15
upgrade
Buy
Reason
Guggenheim analyst Seamus Fernandez raised the firm's price target on Amylyx to $25 from $17 and keeps a Buy rating on the shares. Continued diligence on the post-bariatric hypoglycemia market opportunity and recent comps analysis increases the firm's conviction that Amylyx is "uniquely positioned to deliver on the PBH market's blockbuster potential and become the next big player in rare metabolic disorders," the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Amylyx Pharmaceuticals Inc (AMLX.O) is -9.61, compared to its 5-year average forward P/E of 1.02. For a more detailed relative valuation and DCF analysis to assess Amylyx Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
1.02
Current PE
-9.61
Overvalued PE
14.49
Undervalued PE
-12.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.84
Undervalued EV/EBITDA
-10.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
645.69
Current PS
0.00
Overvalued PS
3702.08
Undervalued PS
-2410.69
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AMLX News & Events

Events Timeline

(ET)
2025-11-06
08:17:52
Amylyx Announces Q3 EPS of 37 Cents, Below Consensus Estimate of 43 Cents
select
2025-09-10 (ET)
2025-09-10
06:37:59
Amylyx Prices 17.5M Share Spot Secondary Offering at $10.00
select
2025-09-09 (ET)
2025-09-09
16:02:51
Amylyx Reveals Common Stock Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-29PRnewswire
Halper Sadeh Investigates Amylyx Pharmaceuticals for Potential Fiduciary Breaches
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Amylyx Pharmaceuticals breached their fiduciary duties, which could impact corporate governance and shareholder rights.
  • Legal Relief Options: Long-term shareholders of Amylyx may seek corporate governance reforms, fund recovery, or court-approved financial incentives, which would enhance the company's transparency and accountability.
  • Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value and demonstrating the company's commitment to shareholder interests.
  • Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, reducing the financial burden of participation.
[object Object]
Preview
8.0
11-07NASDAQ.COM
December 2026 Options for Amylyx Pharmaceuticals (AMLX) Now Accessible

  • Put Contract Overview: The $12.00 strike put contract has a bid of $3.00, allowing investors to buy shares at an effective cost of $9.00, which is attractive compared to the current price of $12.23. There is a 76% chance the contract may expire worthless, potentially yielding a 25% return on cash commitment.

  • Call Contract Overview: The $15.00 strike call contract has a bid of $3.00, and if shares are purchased at $12.23 and the call is sold, it could yield a total return of 47.18% if exercised by December 2026. There is a 31% chance this contract may also expire worthless, allowing the investor to keep both the shares and the premium.

  • Volatility Insights: The implied volatility for the put contract is 125%, while for the call contract it is 121%. The actual trailing twelve-month volatility is calculated at 77%, indicating a significant difference between implied and actual market volatility.

  • YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 22.48% annualized return if it expires worthless, and the call offering a 22.05% annualized return under similar conditions.

[object Object]
Preview
9.5
11-06Yahoo Finance
Amylyx Pharmaceuticals Stock Declines Following Q3 Earnings Report

  • Stock Performance: Amylyx Pharmaceuticals (AMLX) shares experienced a decline of over 4% in trading on Thursday.

  • Quarterly Results: The drop in share price followed the release of the company's Q3 financial results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Amylyx Pharmaceuticals Inc (AMLX) stock price today?

The current price of AMLX is 14.49 USD — it has increased 1.97 % in the last trading day.

arrow icon

What is Amylyx Pharmaceuticals Inc (AMLX)'s business?

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.

arrow icon

What is the price predicton of AMLX Stock?

Wall Street analysts forecast AMLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMLX is 20.22 USD with a low forecast of 16.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Amylyx Pharmaceuticals Inc (AMLX)'s revenue for the last quarter?

Amylyx Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Amylyx Pharmaceuticals Inc (AMLX)'s earnings per share (EPS) for the last quarter?

Amylyx Pharmaceuticals Inc. EPS for the last quarter amounts to -0.37 USD, decreased -65.42 % YoY.

arrow icon

What changes have occurred in the market's expectations for Amylyx Pharmaceuticals Inc (AMLX)'s fundamentals?

The market is revising No Change the revenue expectations for Amylyx Pharmaceuticals, Inc. (AMLX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 42.06%.
arrow icon

How many employees does Amylyx Pharmaceuticals Inc (AMLX). have?

Amylyx Pharmaceuticals Inc (AMLX) has 123 emplpoyees as of December 05 2025.

arrow icon

What is Amylyx Pharmaceuticals Inc (AMLX) market cap?

Today AMLX has the market capitalization of 1.59B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free